ERRATA [Errata]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Tags: Errata Source Type: research

Final Survival Analysis of ROSE/TRIO-012 [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Mackey, McCarthy, Gelmon, Verma, Fresco, Thireau, Fung, Martin Tags: CORRESPONDENCE Source Type: research

Reply to D.J. Sargent et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Glimelius, Hohenberger, Matzel, Sugihara, Quirke Tags: CORRESPONDENCE Source Type: research

Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Sargent, Andre, Grothey Tags: CORRESPONDENCE Source Type: research

Reply to E. Roca et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Nyame, Murphy, Jordan, Gogana, Hollowell, Catalona, Kittles Tags: CORRESPONDENCE Source Type: research

Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Roca, Valcamonico, Amoroso, Antonelli, Foroni, Simeone, Berruti Tags: CORRESPONDENCE Source Type: research

Reply to S. Kaur et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Jacola, Krull, Pui, Pei, Cheng, Reddick, Conklin Tags: CORRESPONDENCE Source Type: research

Demystifying the Association of Chemotherapy and Cognition: How Close Are We? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Kaur, Sharma, Rastogi Tags: CORRESPONDENCE Source Type: research

Reply to L. Zong et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Qi, Hu, Liu, Yu, Li Tags: CORRESPONDENCE Source Type: research

Randomized Controlled Trial of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: How Should We Define the Age of Included Patents? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Zong, Abe, Seto, Ji Tags: CORRESPONDENCE Source Type: research

Delivery [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: MacDonell-Yilmaz Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review [REVIEW ARTICLE]
Conclusion This study is the most comprehensive systematic review of patient navigation research focused on improving breast cancer treatment and survivorship. Minimal research has indicated that patient navigation may be effective for post-treatment surveillance; however, more studies are needed to draw definitive conclusions about the efficacy of patient navigation during and after cancer treatment. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Baik, Gallo, Wells Tags: Surgery, Radiation, Chemotherapy, Hormonal Therapy, Outcomes Research, Quality of Care, Supportive Care REVIEW ARTICLE Source Type: research

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival [Sarcomas]
In this study, we aimed to compare the effectiveness of various radiologic response assessments for the prediction of overall survival (OS) within the same data set of patients with sarcoma. Methods We analyzed assessments made during a clinical trial of a novel IGF1R antibody in Ewing sarcoma: PET Response Criteria in Solid Tumors (PERCIST) for functional imaging and WHO criteria (performed locally and centrally), RECIST, and volumetric analysis for anatomic imaging. We compared the effectiveness of the various criteria for the prediction of progression and survival. Results For volume analysis, progression—define...
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Koshkin, Bolejack, Schwartz, Wahl, Chugh, Reinke, Zhao, O, Patel, Schuetze, Baker Tags: Solid Tumors (Pediatric), Ewing Sarcoma, Osteosarcoma & Ewing Sarcomas:, Translational Oncology, Nuclear Medicine, CT, MRI, Sarcomas Source Type: research

Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis [Head and Neck Cancer]
Conclusion The current study confirms that iDTC is common, but the observed increasing incidence is not mirrored by prevalence within autopsy studies and, therefore, is unlikely to reflect a true population-level increase in tumorigenesis. This strongly suggests that the current increasing incidence of iDTC most likely reflects diagnostic detection increasing over time. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Furuya-Kanamori, Bell, Clark, Glasziou, Doi Tags: Epidemiology, Diagnosis & Staging Head and Neck Cancer Source Type: research

Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer [Epidemiology]
Purpose The effects of obesity and metabolic dysregulation on cancer survival are inconsistent. To identify high-risk subgroups of obese patients and to examine the joint association of metabolic syndrome (MetSyn) in combination with obesity, we categorized patients with early-stage (I to III) colorectal cancer (CRC) into four metabolic categories defined by the presence of MetSyn and/or obesity and examined associations with survival. Methods We studied 2,446 patients diagnosed from 2006 to 2011 at Kaiser Permanente. We assumed MetSyn if patients had three or more of five components present at diagnosis: fasting glucose&...
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Cespedes Feliciano, Kroenke, Meyerhardt, Prado, Bradshaw, Dannenberg, Kwan, Xiao, Quesenberry, Weltzien, Castillo, Caan Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.), Epidemiology Source Type: research

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations [Urologic Oncology]
Purpose Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes in patients with metastatic RCC. Methods The impact of BMI (high BMI: ≥ 25 kg/m2 v low BMI:
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Albiges, Hakimi, Xie, McKay, Simantov, Lin, Lee, Rini, Srinivas, Bjarnason, Ernst, Wood, Vaishamayan, Rha, Agarwal, Yuasa, Pal, Bamias, Zabor, Skanderup, Furberg, Fay, de Velasco, Preston, Wilson, Cho, McDermott, Signoretti, Heng, Choueiri Tags: Behavioral and Lifestyle Risk Factors, Chemotherapy, Epidemiology, Translational Oncology, Genitourinary Urologic Oncology Source Type: research

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy [Urologic Oncology]
Purpose We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. Methods Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. Results Overall, 2,460 patient...
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Tendulkar, Agrawal, Gao, Efstathiou, Pisansky, Michalski, Koontz, Hamstra, Feng, Liauw, Abramowitz, Pollack, Anscher, Moghanaki, Den, Stephans, Zietman, Lee, Kattan, Stephenson Tags: Surgery, Radiation, Combined Modality Therapy, Combined Modality Therapy Urologic Oncology Source Type: research

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion Despite improved progression-free survival on therapy that did not contain erlotinib for KRAS mut+ patients and improved prognosis for mesenchymal tumors, better biomarker-driven treatment strategies are still needed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Papadimitrakopoulou, Lee, Wistuba, Tsao, Fossella, Kalhor, Gupta, Byers, Izzo, Gettinger, Goldberg, Tang, Miller, Skoulidis, Gibbons, Shen, Wei, Diao, Peng, Wang, Tam, Coombes, Koo, Mauro, Rubin, Heymach, Hong, Herbst Tags: Translational Oncology, Chemotherapy, Lung Thoracic Oncology Source Type: research

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies [Hematologic Malignancy]
This study aimed to determine the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [18F]fluorodeoxyglucose/positron emission tomography-computed tomography ([18F]FDG/PET-CT) scans and its added value to these models. Patients and Methods A pooled analysis was performed by using patient data and centrally reviewed baseline PET-CT scans for 185 patients with FL who were receiving immunochemotherapy within three prospective trials. TMTV was computed by using the 41% maximum standardized uptake value thresholding method, and the optimal cutoff for survival prediction was determined. Resu...
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Meignan, Cottereau, Versari, Chartier, Dupuis, Boussetta, Grassi, Casasnovas, Haioun, Tilly, Tarantino, Dubreuil, Federico, Salles, Luminari, Trotman Tags: Diagnosis & Staging, Nuclear Medicine Hematologic Malignancy Source Type: research

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial [Rapid Communication]
Purpose This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact of patient age. Patients and Methods Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks), stratified by age (≤ 75 v> 75 years), disease stage (International Staging System stage I/II v III), and country. The primary end point was ...
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Hulin, Belch, Shustik, Petrucci, Duhrsen, Lu, Song, Rodon, Pegourie, Garderet, Hunter, Azais, Eek, Gisslinger, Macro, Dakhil, Goncalves, LeBlanc, Romeril, Royer, Doyen, Leleu, Offner, Leupin, Houck, Chen, Ervin-Haynes, Dimopoulos, Facon Tags: Chemotherapy, Biology & Immunology, Rapid Communications Source Type: research

Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Temel, Shaw, Greer Tags: Quality of Care, End of Life, Supportive Care COMMENTS AND CONTROVERSIES Source Type: research

Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. An 84-year-old woman presented with bone pain and lytic bone lesions in April 2010. Diagnosis of multiple...
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Larocca, Palumbo Tags: Oncology Grand Rounds Source Type: research

Value of Extra-Early Initiation of Salvage Radiation for Increasing Prostate-Specific Antigen After Prostatectomy [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Nguyen Tags: Radiation EDITORIALS Source Type: research

Can We Define and Reach Precise Goals for Precision Medicine in Cancer Care? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: West Tags: EDITORIALS Source Type: research

Metabolic Tumor Volume in Lymphoma: Hype or Hope? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Schoder, Moskowitz Tags: EDITORIALS Source Type: research

In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology [FROM THE EDITOR'S DESK]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Authors: Cannistra Tags: From the Editor's Desk, Notes from the Editors Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 11, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Mittakanti, Thomas, Shelton, Makarov, Skolarus, Cooperberg, Chung, Sonn, Brooks, Leppert Tags: CORRESPONDENCE Source Type: research

Reply to T.P. Vassilakopoulos et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Merli, Federico, Luminari Tags: CORRESPONDENCE Source Type: research

Reply to S. Rastogi et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Schwartz Tags: CORRESPONDENCE Source Type: research

HD2000 Update in Hodgkin Lymphoma--ABVD or BEACOPP? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Vassilakopoulos, Johnson Tags: CORRESPONDENCE Source Type: research

Reply to S. Rastogi et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Demetri Tags: CORRESPONDENCE Source Type: research

Trabectedin in Soft Tissue Sarcoma: Have We Hit the Bulls-eye? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Rastogi, Bakhshi Tags: CORRESPONDENCE Source Type: research

Reply to O. Corli et al and M. Lucchesi et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Kaasa Tags: CORRESPONDENCE Source Type: research

Two-Step Approach for Persisting Pain: Learning From Children [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Lucchesi, Sardi Tags: CORRESPONDENCE Source Type: research

Good and Bad Responses to a Pain Therapy: How to Discriminate Between Them? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Corli, Roberto Tags: CORRESPONDENCE Source Type: research

Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy [UNDERSTANDING THE PATHWAY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Zhang, Wang, Hwang, He Tags: Immunology/Immunobiology UNDERSTANDING THE PATHWAY Source Type: research

Industry-Academic Relationship in a New Era of Drug Discovery [REVIEW ARTICLE]
The pharmaceutical industry is entering a renewed period of productivity as a result of advances in the understanding of human biology, particularly in the areas of genetics and immunology. The relationship between industry and academia needs to evolve to maximize the opportunity. In four areas—target identification, the molecule itself, experimental medicine, and larger-scale clinical testing—there are specific needs for academic partnerships that should be open and transparent and include talent, skills, and career development. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Vallance Tags: REVIEW ARTICLE Source Type: research

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors [Immunotherapy]
Conclusion AM0010 has an acceptable toxicity profile with early evidence of antitumor activity, particularly in RCC. These data support the further evaluation of AM0010 both alone and in combination with other immune therapies and chemotherapies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Naing, Papadopoulos, Autio, Ott, Patel, Wong, Falchook, Pant, Whiteside, Rasco, Mumm, Chan, Bendell, Bauer, Colen, Hong, Van Vlasselaer, Tannir, Oft, Infante Tags: Clinical Trials, Phase I and Clinical Pharmacology Immunotherapy Source Type: research

How Does Caregiver Well-Being Relate to Perceived Quality of Care in Patients With Cancer? Exploring Associations and Pathways [Health Services and Outcomes]
Conclusion Informal caregivers are an important part of the care team and their well-being is associated with patient-perceived QOC. Engaging informal cancer caregivers as part of the care team and conducting ongoing risk stratification screening and intervention to optimize their health may improve patient-reported outcomes and QOC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Litzelman, Kent, Mollica, Rowland Tags: Quality of Care, Quality of Life, Quality of Care, Supportive Care Health Services and Outcomes Source Type: research

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008 [Hematologic Malignancy]
Purpose Extramedullary disease (EMD) at diagnosis in patients with acute myeloid leukemia (AML) has been recognized for decades. Reported herein are results from a large study of patients with AML who were treated in consecutive ECOG-ACRIN Cancer Research Group frontline clinical trials in an attempt to define the incidence and clinical implications of EMD. Methods Patients with newly diagnosed AML, age 15 years and older, who were treated in 11 clinical trials, were studied to identify EMD, as defined by physical examination, laboratory findings, and imaging results. Results Of the 3,522 patients enrolled, 282 were excl...
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Ganzel, Manola, Douer, Rowe, Fernandez, Paietta, Litzow, Lee, Luger, Lazarus, Cripe, Tallman Tags: Diagnosis & Staging Hematologic Malignancy Source Type: research

Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study [Pediatric Oncology]
Purpose Vinblastine monotherapy has shown promising activity and a low-toxicity profile in patients with pediatric low-grade glioma (PLGG) who experienced treatment failure after initial treatment with chemotherapy and/or radiation. The aim of this study was to assess the activity of vinblastine in therapy-naïve children. Patients and Methods Patients
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Lassaletta, Scheinemann, Zelcer, Hukin, Wilson, Jabado, Carret, Lafay-Cousin, Larouche, Hawkins, Pond, Poskitt, Keene, Johnston, Eisenstat, Krishnatry, Mistry, Arnoldo, Ramaswamy, Huang, Bartels, Tabori, Bouffet Tags: Brain Tumors, Chemotherapy, CNS Tumors Pediatric Oncology Source Type: research

Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base [Urologic Oncology]
Purpose Evidence from studies of other malignancies has indicated that aggressive local treatment (LT), even in the presence of metastatic disease, is beneficial. Against a backdrop of stagnant mortality rates for metastatic urothelial carcinoma of the bladder (mUCB) at presentation, we hypothesized that high-intensity LT of primary tumor burden, defined as the receipt of radical cystectomy or ≥ 50 Gy of radiation therapy delivered to the bladder, affects overall survival (OS). Patients and Methods We identified 3,753 patients within the National Cancer Data Base who received multiagent systemic chemotherapy combined w...
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Seisen, Sun, Leow, Preston, Cole, Gelpi-Hammerschmidt, Hanna, Meyer, Kibel, Lipsitz, Nguyen, Bellmunt, Choueiri, Trinh Tags: Combined Modality Therapy Urologic Oncology Source Type: research

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials [Breast Cancer]
Purpose ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the evaluation of human epidermal growth factor receptor 2 gene (HER2) amplification by fluorescent in situ hybridization (FISH). We retrospectively assessed the impact of these new guidelines by using annotated Breast Cancer International Research Group (BCIRG) -005, BCIRG-006, and BCIRG-007 clinical trials data for which we have detailed outcomes. Patients and Methods The HER2 FISH status of BCIRG-005/006/007 patients with breast cancers was re-evaluated according to current ASCO-CAP guidelines, which designates five...
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Press, Sauter, Buyse, Fourmanoir, Quinaux, Tsao-Wei, Eiermann, Robert, Pienkowski, Crown, Martin, Valero, Mackey, Bee, Ma, Villalobos, Campeau, Mirlacher, Lindsay, Slamon Tags: Diagnosis & Staging, Combined Modality, Clinical Trials, Prognostic Studies, ASCO Guidelines, Breast Cancer, Cancer Biomarkers, Growth Factors & Receptor, Oncogenes Source Type: research

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab [Breast Cancer]
Conclusion Tumor response rates were lower than in prior reports of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-DM1 for ≥ 6 months, which suggests a clinically relevant benefit in patients who received prior pertuzumab. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Dzimitrowicz, Berger, Vargo, Hood, Abdelghany, Raghavendra, Tripathy, Valero, Hatzis, Pusztai, Murthy Tags: Chemotherapy Breast Cancer Source Type: research

Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines [Rapid Communication]
Purpose In 1998, the US Food and Drug Administration (FDA) approved human epidermal growth factor receptor 2 (HER2) testing guidelines to determine eligibility for HER2-directed therapy (HDT) in breast cancer. ASCO and the College of American Pathologists published immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) HER2 testing guidelines in 2007 (AC2007) and updated these guidelines in 2013 (AC2013). We compared the HER2 FISH amplification frequency using these three guidelines. Methods Patient samples that were sent to the Mayo Clinic cytogenetics laboratory for FISH testing (n = 2,851; from Novembe...
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Shah, Wiktor, Meyer, Tenner, Ballman, Green, Sukov, Ketterling, Perez, Jenkins Tags: Diagnosis & Staging, Combined Modality, Prognostic Studies, ASCO Guidelines, Rapid Communications Source Type: research

Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Shoag, Schlegel, Hu Tags: Non-ASCO Guidelines, Diagnosis & Staging COMMENTS AND CONTROVERSIES Source Type: research